APC is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [3].

CTNNB1 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain CTNNB1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

GLI2 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain GLI2 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KMT2C is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KMT2C status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains MYC status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [3].

MYCL is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MYCL status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

MYCN is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PPM1D status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PTEN is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [3].

SHH is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SHH status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SMO is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SNCAIP status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

SUFU is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SUFU status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

TERT is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain TERT status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

YAP1 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain YAP1 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain ZMYM3 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [3].